Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 22, 2026
TickeronGET DAILY SIGNALS
Talphera (TLPH): The +299% Jump to the $3.13 Target

Talphera (TLPH): The +299% Jump to the $3.13 Target

Key Takeaways

  • The central target used here is $3.13, the arithmetic mean of four verified analyst price targets, which range from $3.00 to $3.50.
  • That target sits roughly 299% above the latest verified price of about $0.79 (Nov. 20, 2026 close), making the required move extremely large.
  • Every collected target is a Buy, reflecting optimism about Niyad's regulatory path, but the shares carry substantial binary, clinical-trial risk.
  • The bullish case hinges on FDA feedback on an early close of the NEPHRO CRRT study and a potential PMA (premarket approval) filing in 2027.
  • Key risks include slow trial enrollment, possible dilution, and a tiny cash base relative to the program's timeline.
  • For more on the company, explore Major News, Today's Price Move, the Forecast page, and Earnings coverage.
  • Investors tracking this name may also want to review Trending AI Robots for automated signal ideas across the market.

Analyst Price Targets and Consensus View

The central $3.13 target is the average of four individually verified analyst price targets, a low-to-high range of $3.00 to $3.50. Maxim Group's Naz Rahman reiterated a Buy with a $3.00 target on Nov. 14, 2026, and H.C. Wainwright's Brandon Folkes reiterated Buy at $3.00 on Nov. 13, 2026. Alliance Global Partners maintained a $3.50 target in May 2026, while Westpark Capital initiated coverage at $3.00 in April 2026. All four are Buy ratings, so the "analyst consensus" leans bullish despite the very wide gap between price and target. The $3.13 figure is a calculated mean, not a formal published consensus, and reflects the stock's deep-value, pre-approval status rather than any near-term earnings momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

With the latest verified price near $0.79 and a 52-week range of roughly $0.69 to $1.57, reaching $3.13 would require a gain of about 299%, a very large move for any equity and an exceptional one for a pre-revenue biopharmaceutical. The path is almost entirely event-driven. Talphera has asked the FDA for a "Sprint Meeting" to discuss closing enrollment in its NEPHRO CRRT registrational study by Dec. 31, 2026, even if the original 70-patient target is not fully met, citing that the study remains over 80% powered for its primary endpoint. Topline data would follow roughly four to six weeks after enrollment closes, with a potential PMA submission and approval targeted for 2027.

What Could Support a Move Toward the Target

Talphera has raised its estimate of Niyad's peak annual U.S. sales in CRRT to more than $200 million, citing quantitative physician research. Niyad holds FDA Breakthrough Device Designation, and management has flagged supportive industry developments, including updated KDIGO (Kidney Disease: Improving Global Outcomes) draft guidelines that elevate nafamostat as an alternative anticoagulant, and a New England Journal of Medicine study favoring CRRT over intermittent hemodialysis. A $14.2 million cash balance with no debt, plus roughly $16 million in conditional financing tranches, is expected to fund the program toward a potential approval.

What Could Prevent the Target From Being Reached

The risks are substantial. Enrollment in the NEPHRO CRRT study has slowed sharply, with management reporting an 85%–90% drop in consented patients versus the prior-year period. If the FDA declines the early-closure request, enrollment would continue toward 70 patients, potentially delaying topline data and the PMA timeline. The company also plans to file a new Form S-3 shelf registration, a signal of possible future dilution. As a pre-revenue company with a market capitalization near $40 million and quarterly operating losses of roughly $4 million, any regulatory setback could pressure the share price materially.

Technical Levels and Market Structure

The shares have been consolidating in a broad range, with the 52-week low near $0.69 acting as a key support level and the year's high near $1.57 serving as overhead resistance. A decisive move above the $1.00 psychological level would be an early sign of improving structure, while the $1.50 area represents the next meaningful resistance zone before any attempt on higher levels. Given the thin trading and event-driven nature of the stock, technical levels are secondary to regulatory catalysts. From what I see, combining this with AI-driven pattern tools helps keep the focus on the bigger picture.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month horizon, though for Talphera they are effectively tied to the clinical and regulatory timeline rather than earnings. The most important near-term items are the FDA's response to the Sprint Meeting request, expected before year-end, followed by NEPHRO CRRT topline data, the closure of conditional financing tranches, and any update on the PMA filing. Investors should also watch the cash runway, enrollment commentary, and any new shelf-registration or equity financing activity. I’m watching this closely as the regulatory updates unfold.

Leveraging Tickeron’s AI Daily Buy/Sell Signals

For traders who want a more systematic view of shifting conditions, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening allows. For a volatile, event-driven name like TLPH, combining AI-generated signals with fundamental and regulatory research can add a useful layer of discipline to the decision process. In my view, this has become a regular part of how I cross-check ideas before making any moves.

Final Assessment

The $3.13 stock price target is a calculated average of four Buy-rated analyst targets spanning $3.00 to $3.50, and it sits roughly 299% above the latest price. Reaching it depends almost entirely on the FDA allowing an early close of the NEPHRO CRRT study, favorable topline data, and a successful PMA filing and approval in 2027. The bullish case is grounded in Niyad's Breakthrough Device Designation, an expanded $200 million-plus peak sales estimate, and supportive guidelines and clinical literature. The bearish case rests on slowing enrollment, financing and dilution risk, and the binary nature of regulatory outcomes. There is no guarantee the stock approaches, reaches, or sustains that level; investors should monitor FDA feedback and topline data as the decisive catalysts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TLPH

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for TLPH turns negative, indicating new downward trend

TLPH saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 85 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TLPH turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLPH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLPH advanced for three days, in 179 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

TLPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TLPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.783) is normal, around the industry mean (6.379). P/E Ratio (-4.565) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (183.387).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 38% and the average quarterly volume growth was 47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 63
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 6 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of innovative therapies for the treatment of acute and breakthrough pain

Industry PharmaceuticalsGeneric

Industry
Pharmaceuticals Other
Address
1850 Gateway Drive
Phone
+1 650 216-3500
Employees
12
Web
https://www.talphera.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.